MegaPro Biomedical Co., Ltd.
Embedded Files
Translating proprietary nanomedicine platforms into five clinical-stage assets for innovative clinical solutions.
Competitors
Competitors
Bayer (Germany)
US Office
US Office
Will set up a company in 2027 in California
Fundraising Status
Fundraising Status
Total Funds Raised: $45M
Series C or above, 2026Q4
Fundraising Target: 6M
Company Details
Business Overview
Business Overview
MegaPro Biomedical is a clinical-stage company specializing in translating proprietary nanomedicine into innovative clinical solutions. Its core Nano-Particle Platform (505b1) utilizes PEGylated iron oxide nanoparticles (IOP Injection) to drive a versatile pipeline with broad applications.
This multi-functional platform enables high-resolution diagnostic imaging, such as MPB-1523 for liver cancer (entering Phase III) and MPB-2043 for lymph node metastasis. Beyond diagnostics, it powers MPB-2354, a pioneering "Visible Cell Therapy" for Critical Limb Ischemia, which integrates real-time MRI tracking with enhanced stem cell efficacy.
Furthermore, the platform supports treatments for iron deficiency anemia (MPB-1514) and research into vaccine adjuvants and hyperthermia. By leveraging this scalable technology, MegaPro effectively "opens the black box" of complex therapies, creating a robust roadmap for global expansion and strategic licensing.
Core Technology
Core Technology
MegaPro’s Nano-Particle Platform (505b1) is built on proprietary PEGylated iron oxide nanoparticles (IOP Injection). This biodegradable technology features a non-sugar formulation, significantly reducing hypersensitivity risks while offering high r2 relaxivity for superior MRI contrast.
The platform’s versatility enables a wide clinical roadmap:
1. Precision Diagnostics: Leveraging efficient immune cell phagocytosis for high-resolution imaging of liver cancer (MPB-1523) and lymph node metastasis (MPB-2043).
2. Visible Cell Therapy: In MPB-2354, particles are loaded into stem cells to "open the black box" by enabling real-time in vivo tracking while boosting angiogenic signals (VEGF) by 4-fold.
3. Broad Extensions: The technology also supports treatments for iron deficiency anemia (MPB-1514), vaccine adjuvants, and hyperthermia.
By integrating imaging with therapy, the Nano-Particle platform transforms empirical treatments into data-driven, trackable clinical solutions.
US Objective
Expected Results
Expected Results
Seeking $6M for 10% equity in its U.S. subsidiary, which holds the exclusive license for MPB-2354. Funds will support U.S. FDA IND filing ($2M) and Phase 1 clinical trials ($4M) to validate clinical feasibility.
We seek pharmaceutical partners to out-license MPB-2354 and collaborate on integrating its "Visible Cell Therapy" platform into third-party treatments like CAR-T. Strategic partnerships with global leaders accelerate clinical development and drive market adoption within the $18B "no-option" CLI market, maximizing our technology’s commercial value.
Team Members
Team Members
Jassy Wang
CEO
Media Exposure
Page updated
Report abuse